Franklin FTSE South Korea ETF vs Oruka Therapeutics Inc. Common Stock — how do they compare? Franklin FTSE South Korea ETF trades at $49.47 (market cap $1.67B), while Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.18B). The key difference: Oruka Therapeutics Inc. Common Stock is far larger — about 3.1× Franklin FTSE South Korea ETF's market cap, and Franklin FTSE South Korea ETF is more actively traded (703,703 versus 490,798). Which is the better fit depends on your goals — on Pluang, investors hold Franklin FTSE South Korea ETF for 15 Days and Oruka Therapeutics Inc. Common Stock for 0 Days on average.
| FLKR | ORKA | |
|---|---|---|
Market Cap | $1.67B | $5.18B |
Volume | 703,703 | 490,798 |
Sector | Broad Market / Factor | Health |
52-Week High | $72.25 | $113.08 |
52-Week Low | $28.48 | $26.19 |
Typical Hold Time | 15 Days | 0 Days |
Enterprise Value | — | $4.31B |
Signals from Pluang's Aura AI — not financial advice
FLKR (Franklin FTSE South Korea ETF) is trading at $54.89, down 2.03% with a bearish technical signal (16 sell vs 6 buy signals). The ETF faces pressure from semiconductor sector volatility and rising global yields, though some analysts see current levels as a potential buying opportunity. Technical indicators show strong resistance at $55-$56 with support at $53-$54 levels. The fund remains heavily concentrated in Korean memory chip giants Samsung and SK Hynix, making it highly sensitive to AI and semiconductor cycles.
While FLKR faces near-term headwinds from semiconductor volatility and macroeconomic pressures, long-term prospects remain tied to AI-driven demand for Korean tech. The current discount to growth expectations presents opportunity, but investors must weigh concentration risk against potential semiconductor recovery. Key risks include political tensions, currency fluctuations, and global interest rate environment.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Franklin FTSE South Korea ETF seeks to track an index of South Korean equities. The fund provides exposure to companies listed in South Korea across multiple sectors.
Read more on FLKR →Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →